While there have been enormous advancements in gene therapies, these progress also bring new challenges, from manufacturing complications to safe delivery systems. As a new era of gene therapy ushers in, how are the next generation of genetic therapeutics going to address these issues? In a panel titled A New Era in Gene Therapy on June 15 at the 2022 BIO International Convention, industry experts discussed novel developments that could solve some of the greatest headaches in gene therapy, such as the application of non-viral vectors, improving access to gene therapy for rare and broad indication, and enhancing cost efficiency.

A New Era in Gene Therapy’s panelists included:

• Shankar Ramaswamy, CEO and Founder of Kriya Therapeutics
• Diem Nguyen, CEO of Xalud Therapeutics
• Mathew Pletcher, Division Head of Gene Therapy Research & Technical Operations for Astellas Gene Therapies
• RA Session II, CEO and Founder of Taysha Gene Therapies